UPB compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

UPBUpstream Bio, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

UPBUpstream Bio, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only UPB 5

REGNRegeneron Pharmaceuticalssupplier

—Astellas Pharmaunlistedsupplier

—Lonza Salesunlistedsupplier

—Wuxi Biologics (Hong Kong)unlistedsupplier

1 more · UPB chain ›

Shared 0

No shared counterparties.

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

25 more · LLY chain ›

UPBUpstream Bio, Inc.

3.21▼−13.24%· post 3.38

Mkt cap$175.2MRevenue$773,000Q2 FY26Revenue$3MFY25

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,363.77

ClosedNov 5 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 5 '26

UPBUpstream Bio, Inc.

LLYELI Lilly & Co

3.21▼−13.24%post 3.38

Price

1,371.32▼−3.29%post 1,363.77

$175.2M

Mkt cap

$1.2T

Q2 FY26$773,000

Revenue

$24.4BQ3 FY26

FY25$3M

Revenue

$65.2BFY25

UPB3.21▼−13.24%vsLLY1,371.32▼−3.29%ClosedNov 5 '26